Xbiotech Inc. (XBIT): W Thorpe Mckenzie , director 10% owner of Xbiotech Inc. purchased 20,000 shares on May 26, 2016. The Insider buying transaction was reported by the company on May 26, 2016 to the Securities and Exchange Commission. The shares were purchased at $13.96 per share for a total value of $279,115.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 20, 2016, W Thorpe Mckenzie (director 10% owner) purchased 1,500 shares at $13.75 per share price.On Dec 23, 2015, Queena Han (VP Finance / HR) sold 30,000 shares at $10.51 per share price.Also, On Nov 19, 2015, Michael Stecher (Medical Director) sold 1,800 shares at $14.00 per share price.
Shares of XBiotech Inc (XBIT) ended Wednesday, May 25, 2016 session in red amid volatile trading. The shares closed down -0.14 points or -1.00% at $13.86 with 93,393 shares getting traded. Post opening the session at $13.95, the shares hit an intraday low of $13.65 and an intraday high of $14.16 and the price vacillated in this range throughout the day. The company has a market cap of $448 M and the number of outstanding shares has been calculated to be 3,23,50,565 shares. The 52-week high of XBiotech Inc is $22.9 and the 52-week low is $6.36.
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Humanmonoclonal antibodies for treating various diseases. The Company focuses to develop MABp1 a therapeutic antibody which specifically neutralizes interleukin-1 alpha (IL-1a). IL-1a is a pro-inflammatory protein produced by leukocytes and other cells where it plays arole in inflammation. The Company has completed a Phase I/II clinical trials for MABp1 (Xilonix) as a treatment for cancer at MD Anderson Cancer Center. The Company is also involved in investigating MABp1 in clinical trials for other indicationsincluding vascular disease type II diabetes acne and psoriasis. The Company has begun using its True Human antibody technology for developing a therapy for Ebola virus infection.